Breaking News Instant updates and real-time market news.

XENE

Xenon Pharmaceuticals

$10.30

0.65 (6.74%)

14:12
07/13/18
07/13
14:12
07/13/18
14:12

Vivo Opportunity reports 5.6% passive stake in Xenon Pharmaceuticals

XENE Xenon Pharmaceuticals
$10.30

0.65 (6.74%)

03/22/18
JEFF
03/22/18
NO CHANGE
Target $6
JEFF
Buy
Xenon Pharmaceuticals price target raised to $6 from $5 at Jefferies
Jefferies analyst Maury Raycroft raised his price target for Xenon Pharmaceuticals to $6 and keeps a Buy rating on the shares after traveling with management. The analyst sees 2018 as a key year for the company with data readouts in epilepsy. Initial data in May will likely move the stock, Raycroft tells investors in a research note.
06/13/18
JEFF
06/13/18
NO CHANGE
Target $9
JEFF
Buy
Sage update yesterday positive for Xenon, says Jefferies
Jefferies analyst Maury Raycroft believes Sage Therapeutics' (SAGE) FDA approval to accelerate a development path for '217 in major depressive disorder and postpartum depression provides a positive read-through for Xenon Pharmaceuticals (XENE). Xenon has two epilepsy programs and one program for hemiplegic migraine, which all have potential in rare disease indications with broader applicability, Raycroft tells investors in a research note. He believes "recent derisking" provides a "great entry point" into Xenon Pharmaceuticals at current share levels. The analyst has a Buy rating on the shares with a $9 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.